Vision 2020 Right to Sight strategies achievements challenges corneal blindness ophthalmology

Vision 2020 corneal blindness strategies India eye bank trachoma xerophthalmia HSV keratitis challenges 2020

https://pmc.ncbi.nlm.nih.gov/articles/PMC3831688

ls /home/daytona/workspace/ 2>/dev/null && ls /home/daytona/skills/docx/scripts/…

mkdir -p /home/daytona/workspace/vision2020-docx

~/vision2020-docx/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, PageBreak,
  TableOfContents, UnderlineType
} = require('docx');
const fs = require('fs');

// ── colour palette ──────────────────────────────────────────────────────────
const DARK_BLUE   = "1F3864";
const MED_BLUE    = "2E74B5";
const LIGHT_BLUE  = "D6E4F0";
const ACCENT_GOLD = "C9A800";
const DARK_GOLD   = "7D6800";
const PALE_GOLD   = "FFF8DC";
const WHITE       = "FFFFFF";
const LIGHT_GRAY  = "F2F2F2";
const DARK_GRAY   = "404040";
const RED_ACCENT  = "C00000";
const GREEN_ACC   = "375623";
const PALE_GREEN  = "E2EFDA";

// ── helpers ──────────────────────────────────────────────────────────────────
const pt = n => n * 2;   // half-points

function coverTitle(text) {
  return new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: pt(6), after: pt(4) },
    children: [new TextRun({
      text, bold: true, color: WHITE, size: pt(32), font: "Calibri"
    })]
  });
}

function coverSub(text) {
  return new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: pt(3), after: pt(3) },
    children: [new TextRun({
      text, color: LIGHT_BLUE, size: pt(16), font: "Calibri", italics: true
    })]
  });
}

function sectionHeading(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_1,
    spacing: { before: pt(16), after: pt(6) },
    shading: { type: ShadingType.SOLID, color: DARK_BLUE, fill: DARK_BLUE },
    children: [new TextRun({
      text: "  " + text, bold: true, color: WHITE, size: pt(15), font: "Calibri",
      allCaps: true
    })]
  });
}

function subHeading(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_2,
    spacing: { before: pt(10), after: pt(4) },
    children: [new TextRun({
      text, bold: true, color: MED_BLUE, size: pt(13), font: "Calibri"
    })]
  });
}

function subSubHeading(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_3,
    spacing: { before: pt(8), after: pt(3) },
    children: [new TextRun({
      text, bold: true, color: DARK_GRAY, size: pt(12), font: "Calibri",
      underline: { type: UnderlineType.SINGLE, color: MED_BLUE }
    })]
  });
}

function para(text, opts = {}) {
  return new Paragraph({
    spacing: { before: pt(3), after: pt(3) },
    children: [new TextRun({
      text, size: pt(11), font: "Calibri", color: DARK_GRAY,
      bold: opts.bold || false, italics: opts.italic || false
    })]
  });
}

function bulletItem(text, level = 0) {
  const indent = level === 0
    ? { left: 360, hanging: 360 }
    : { left: 720, hanging: 360 };
  return new Paragraph({
    spacing: { before: pt(2), after: pt(2) },
    indent,
    children: [
      new TextRun({ text: level === 0 ? "• " : "– ", bold: true, color: MED_BLUE, size: pt(11), font: "Calibri" }),
      new TextRun({ text, size: pt(11), font: "Calibri", color: DARK_GRAY })
    ]
  });
}

function highlightBullet(label, value) {
  return new Paragraph({
    spacing: { before: pt(2), after: pt(2) },
    indent: { left: 360, hanging: 360 },
    children: [
      new TextRun({ text: "▶ ", bold: true, color: ACCENT_GOLD, size: pt(11), font: "Calibri" }),
      new TextRun({ text: label + ": ", bold: true, color: DARK_BLUE, size: pt(11), font: "Calibri" }),
      new TextRun({ text: value, size: pt(11), font: "Calibri", color: DARK_GRAY })
    ]
  });
}

function importantBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [new TableRow({ children: [new TableCell({
      shading: { type: ShadingType.SOLID, color: PALE_GOLD, fill: PALE_GOLD },
      borders: {
        top: { style: BorderStyle.THICK, size: 6, color: ACCENT_GOLD },
        bottom: { style: BorderStyle.THICK, size: 6, color: ACCENT_GOLD },
        left: { style: BorderStyle.THICK, size: 12, color: DARK_GOLD },
        right: { style: BorderStyle.THICK, size: 6, color: ACCENT_GOLD }
      },
      margins: { top: 100, bottom: 100, left: 200, right: 100 },
      children: [new Paragraph({
        children: [
          new TextRun({ text: "★ EXAM POINT: ", bold: true, color: DARK_GOLD, size: pt(11), font: "Calibri" }),
          new TextRun({ text, size: pt(11), font: "Calibri", color: DARK_GRAY, italics: true })
        ]
      })]
    })]})],
  });
}

function warningBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [new TableRow({ children: [new TableCell({
      shading: { type: ShadingType.SOLID, color: "FFE6E6", fill: "FFE6E6" },
      borders: {
        top: { style: BorderStyle.THICK, size: 4, color: RED_ACCENT },
        bottom: { style: BorderStyle.THICK, size: 4, color: RED_ACCENT },
        left: { style: BorderStyle.THICK, size: 12, color: RED_ACCENT },
        right: { style: BorderStyle.THICK, size: 4, color: RED_ACCENT }
      },
      margins: { top: 100, bottom: 100, left: 200, right: 100 },
      children: [new Paragraph({
        children: [
          new TextRun({ text: "⚠ CHALLENGE / CHALLENGE POINT: ", bold: true, color: RED_ACCENT, size: pt(11), font: "Calibri" }),
          new TextRun({ text, size: pt(11), font: "Calibri", color: DARK_GRAY })
        ]
      })]
    })]})],
  });
}

function greenBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [new TableRow({ children: [new TableCell({
      shading: { type: ShadingType.SOLID, color: PALE_GREEN, fill: PALE_GREEN },
      borders: {
        top: { style: BorderStyle.THICK, size: 4, color: GREEN_ACC },
        bottom: { style: BorderStyle.THICK, size: 4, color: GREEN_ACC },
        left: { style: BorderStyle.THICK, size: 12, color: GREEN_ACC },
        right: { style: BorderStyle.THICK, size: 4, color: GREEN_ACC }
      },
      margins: { top: 100, bottom: 100, left: 200, right: 100 },
      children: [new Paragraph({
        children: [
          new TextRun({ text: "✔ ACHIEVEMENT: ", bold: true, color: GREEN_ACC, size: pt(11), font: "Calibri" }),
          new TextRun({ text, size: pt(11), font: "Calibri", color: DARK_GRAY })
        ]
      })]
    })]})],
  });
}

function spacer(n = 1) {
  return new Paragraph({ spacing: { before: pt(n * 4), after: pt(n * 4) }, children: [] });
}

function makeTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) => new TableCell({
      width: colWidths ? { size: colWidths[i], type: WidthType.PERCENTAGE } : undefined,
      shading: { type: ShadingType.SOLID, color: DARK_BLUE, fill: DARK_BLUE },
      verticalAlign: VerticalAlign.CENTER,
      margins: { top: 80, bottom: 80, left: 120, right: 120 },
      children: [new Paragraph({
        alignment: AlignmentType.CENTER,
        children: [new TextRun({ text: h, bold: true, color: WHITE, size: pt(10), font: "Calibri" })]
      })]
    }))
  });

  const dataRows = rows.map((row, ri) => new TableRow({
    children: row.map((cell, ci) => new TableCell({
      width: colWidths ? { size: colWidths[ci], type: WidthType.PERCENTAGE } : undefined,
      shading: {
        type: ShadingType.SOLID,
        color: ri % 2 === 0 ? WHITE : LIGHT_GRAY,
        fill: ri % 2 === 0 ? WHITE : LIGHT_GRAY
      },
      margins: { top: 60, bottom: 60, left: 120, right: 120 },
      children: [new Paragraph({
        children: [new TextRun({ text: cell, size: pt(10), font: "Calibri", color: DARK_GRAY })]
      })]
    }))
  }));

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    borders: {
      top: { style: BorderStyle.SINGLE, size: 2, color: MED_BLUE },
      bottom: { style: BorderStyle.SINGLE, size: 2, color: MED_BLUE },
      left: { style: BorderStyle.SINGLE, size: 2, color: MED_BLUE },
      right: { style: BorderStyle.SINGLE, size: 2, color: MED_BLUE },
      insideH: { style: BorderStyle.SINGLE, size: 1, color: "BBBBBB" },
      insideV: { style: BorderStyle.SINGLE, size: 1, color: "BBBBBB" }
    },
    rows: [headerRow, ...dataRows]
  });
}

// ── DOCUMENT CONTENT ─────────────────────────────────────────────────────────
const children = [];

// ─── COVER BLOCK ─────────────────────────────────────────────────────────────
const coverTable = new Table({
  width: { size: 100, type: WidthType.PERCENTAGE },
  rows: [new TableRow({ children: [new TableCell({
    shading: { type: ShadingType.SOLID, color: DARK_BLUE, fill: DARK_BLUE },
    margins: { top: 400, bottom: 400, left: 400, right: 400 },
    children: [
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(4), after: pt(2) },
        children: [new TextRun({ text: "VISION 2020", bold: true, color: ACCENT_GOLD, size: pt(36), font: "Calibri", allCaps: true })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(1), after: pt(4) },
        children: [new TextRun({ text: "The Right to Sight", bold: true, color: WHITE, size: pt(22), font: "Calibri", italics: true })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(2), after: pt(2) },
        children: [new TextRun({ text: "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━", color: ACCENT_GOLD, size: pt(9), font: "Calibri" })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(3), after: pt(2) },
        children: [new TextRun({ text: "Comprehensive Exam-Ready Summary", color: LIGHT_BLUE, size: pt(15), font: "Calibri" })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(1), after: pt(3) },
        children: [new TextRun({ text: "PG Ophthalmology  |  Preventive & Social Medicine", color: LIGHT_BLUE, size: pt(13), font: "Calibri", italics: true })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(2), after: pt(2) },
        children: [new TextRun({ text: "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━", color: ACCENT_GOLD, size: pt(9), font: "Calibri" })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: pt(2), after: pt(2) },
        children: [new TextRun({ text: "Covers: Background • Global Burden • Strategies • Corneal Blindness • Achievements • Challenges • Quick-Recall Tables", color: "AACCEE", size: pt(10), font: "Calibri" })]
      }),
    ]
  })]})],
});
children.push(coverTable);
children.push(spacer(2));

// ─── SECTION 1: INTRODUCTION ─────────────────────────────────────────────────
children.push(sectionHeading("1. Introduction & Background"));
children.push(spacer(0.5));

children.push(subHeading("Launch & Foundation"));
children.push(highlightBullet("Launched by", "WHO + IAPB (International Agency for Prevention of Blindness)"));
children.push(highlightBullet("Date", "18th February 1999"));
children.push(highlightBullet("Concept", "Sight as a fundamental HUMAN RIGHT — unique from prior campaigns"));
children.push(highlightBullet("Core Goal", "Eliminate avoidable blindness from major causes by year 2020"));
children.push(highlightBullet("Successor", "IAPB 2030 IN SIGHT / WHO IPEC framework"));
children.push(spacer());

children.push(importantBox("Vision 2020 was launched on 18th Feb 1999 by WHO + IAPB. The rights-based framework distinguishes it from all previous blindness campaigns."));
children.push(spacer());

children.push(subHeading("Guiding Principle — ISEE"));
children.push(makeTable(
  ["Letter", "Stands For", "Meaning"],
  [
    ["I", "Integration", "Integrate eye care into national health systems"],
    ["S", "Sustainability", "Build systems that last beyond project periods"],
    ["E", "Equity", "Ensure equitable access regardless of geography/income"],
    ["E", "Evidence-based", "Use proven, cost-effective interventions only"],
  ],
  [10, 25, 65]
));
children.push(spacer());

// ─── SECTION 2: GLOBAL BURDEN ────────────────────────────────────────────────
children.push(sectionHeading("2. Global Burden of Blindness"));
children.push(spacer(0.5));

children.push(makeTable(
  ["Indicator", "Figures (WHO 2020)"],
  [
    ["Total blind globally", "43 million"],
    ["Moderate-Severe Visual Impairment (MSVI)", "295 million"],
    ["Mild visual impairment", "257 million"],
    ["VI from uncorrected presbyopia", "507 million"],
    ["Avoidable blindness (preventable + treatable)", "~80% of all cases"],
    ["Blind living in developing countries", "9 out of 10"],
    ["India + China share of world blindness", "~49% (disproportionate to 37% of world population)"],
    ["India — estimated blind (pre-2020)", "~12 million"],
  ],
  [50, 50]
));
children.push(spacer());

children.push(importantBox("80% of all blindness is avoidable — the central justification for Vision 2020. Cataract alone causes ~50% of global blindness."));
children.push(spacer());

children.push(subHeading("Causes Targeted by Vision 2020"));
children.push(makeTable(
  ["Priority Disease", "Global Share", "Strategy"],
  [
    ["Cataract", "~50%", "Cataract Surgical Rate (CSR) improvement"],
    ["Refractive error / Low vision", "~43% of MSVI", "Refraction services, spectacle provision"],
    ["Glaucoma", "~12%", "Early detection, IOP management"],
    ["Trachoma (corneal)", "~3-4%", "SAFE strategy"],
    ["Diabetic retinopathy", "Increasing", "Screening, laser, anti-VEGF"],
    ["Childhood blindness", "~3-4%", "Vit A, ROP screening, congenital cataract"],
    ["Onchocerciasis", "Africa/Americas", "Ivermectin MDA"],
    ["Corneal blindness (overall)", "4–6% in India", "Eye banking, infection prevention, trauma control"],
  ],
  [35, 20, 45]
));
children.push(spacer());

// ─── SECTION 3: STRATEGIES ───────────────────────────────────────────────────
children.push(sectionHeading("3. Strategies of Vision 2020"));
children.push(spacer(0.5));

children.push(subHeading("3.1 Four-Tier Infrastructure (India)"));
children.push(makeTable(
  ["Tier", "Facility", "Target Number", "Functions"],
  [
    ["1st", "Centres of Excellence (CoE)", "20", "Corneal transplant, vitreoretinal, complex surgery, research"],
    ["2nd", "Training Centres", "200", "Ophthalmologist training, advanced procedures, district oversight"],
    ["3rd", "Service / District Centres", "2,000", "Cataract surgery, glaucoma, diabetic screening, mid-level training"],
    ["4th", "Vision Centres (primary)", "20,000", "Screening, refraction, Vit A, basic eye care, referral"],
  ],
  [8, 30, 18, 44]
));
children.push(spacer());

children.push(importantBox("The four-tier pyramid: 20 CoEs — 200 Training Centres — 2000 Service Centres — 20,000 Vision Centres. Frequently asked in exams."));
children.push(spacer());

children.push(subHeading("3.2 National Programme for Control of Blindness & Visual Impairment (NPCB&VI)"));
children.push(bulletItem("Free cataract surgery + spectacles + low-vision devices for BPL patients"));
children.push(bulletItem("Establishment and strengthening of Eye Banks and Eye Retrieval Centres"));
children.push(bulletItem("School eye health screening programs"));
children.push(bulletItem("Training of Mid-Level Ophthalmic Personnel (MLOP)"));
children.push(bulletItem("Vitamin A supplementation: 100,000 IU (< 1 yr) / 200,000 IU (> 1 yr) every 6 months"));
children.push(bulletItem("Trachoma surveillance and graded response"));
children.push(bulletItem("Integration with PHC, ASHA workers, and community health workers"));
children.push(spacer());

children.push(subHeading("3.3 Vision 2020 India — Five Strategic Objectives (2021–2026)"));
children.push(makeTable(
  ["Objective", "Meaning"],
  [
    ["Universalize", "Achieve complete coverage at primary eye care level — ensure no one is left out"],
    ["Consolidate", "Strengthen and build on existing eye care programs and infrastructure"],
    ["Systematize", "Integrate data systems, quality assurance, and referral pathways across all levels"],
    ["Coordinate", "Align activities of NGOs, INGOs, and Government towards common goals"],
    ["Advocate", "Influence policy, mobilize funding, promote eye health in public discourse"],
  ],
  [20, 80]
));
children.push(spacer());

children.push(subHeading("3.4 Global Eye Health Action Plan 2014–2019"));
children.push(bulletItem("Target: 25% reduction in avoidable visual impairment from 2010 baseline by 2019"));
children.push(bulletItem("Built on 5 principles: universal access & equity, human rights, evidence-based practice, life course approach, empowerment of visually impaired"));
children.push(bulletItem("Three national-level indicators: (1) Prevalence/causes of VI; (2) Number of eye care personnel; (3) Cataract Surgical Rate"));
children.push(bulletItem("Addresses ageing population trends — shifting burden towards chronic diseases (DR, glaucoma, AMD)"));
children.push(spacer());

// ─── SECTION 4: CORNEAL BLINDNESS ────────────────────────────────────────────
children.push(sectionHeading("4. Corneal Blindness — Burden & Causes"));
children.push(spacer(0.5));

children.push(subHeading("4.1 Epidemiology"));
children.push(makeTable(
  ["Statistic", "Figures"],
  [
    ["Rank in India (preventable blindness)", "2nd most common cause"],
    ["Bilateral corneal blindness in India", ">1.3 million"],
    ["Unilateral corneal blindness in India (2020)", "~10.6 million (vision < 6/60)"],
    ["Global bilateral corneal blindness", "5.5 million"],
    ["Global unilateral + visual impairment", ">20 million"],
    ["Share of all blindness in India", "4–6%"],
    ["Treatable fraction (keratoplasty candidate)", "~50%"],
    ["Potential blind-years saved if 90% prevented by 2020", "29 million blind-years prevented"],
  ],
  [55, 45]
));
children.push(spacer());

children.push(subHeading("4.2 Causes of Corneal Blindness"));
children.push(makeTable(
  ["Category", "Specific Causes", "Notes"],
  [
    ["Infectious", "Trachoma (C. trachomatis)", "World's leading infectious cause of corneal blindness (WHO)"],
    ["Infectious", "HSV keratitis", "Most common infectious cause in developed countries; 10 million affected globally"],
    ["Infectious", "Bacterial keratitis", "Pseudomonas (contact lens); Streptococcus pneumoniae"],
    ["Infectious", "Fungal keratitis", "Aspergillus (most common in India), Fusarium, Candida — after agricultural trauma"],
    ["Nutritional", "Xerophthalmia / VAD", "Up to 50% of childhood blindness in poor areas; stages: XN → X1A → X1B → X2 → X3A → X3B"],
    ["Traumatic", "Occupational / agricultural injuries", "Vegetable matter → fungal; Chemical burns → limbal stem cell deficiency"],
    ["Traditional eye medicine", "TEM / home remedies", "Major cause in Africa, South Asia — cow urine, plant extracts → direct corneal damage"],
    ["Iatrogenic", "Surgical complications", "Post-PKP graft failure, LASIK ectasia"],
    ["Congenital", "Corneal dystrophies, Peter's anomaly", "Fuchs', macular, lattice dystrophies"],
    ["Immune-mediated", "SJS, MMP, VKC", "Cicatricial ocular surface disease — poor keratoplasty candidates"],
  ],
  [20, 30, 50]
));
children.push(spacer());

// ─── SECTION 5: STRATEGIES FOR CORNEAL BLINDNESS ─────────────────────────────
children.push(sectionHeading("5. Strategies to Address Corneal Blindness"));
children.push(spacer(0.5));

children.push(subHeading("5.1 Trachoma — SAFE Strategy"));
children.push(makeTable(
  ["Letter", "Component", "Details"],
  [
    ["S", "Surgery", "Bilamellar tarsal rotation for trichiasis/entropion — prevents corneal abrasion"],
    ["A", "Antibiotics", "Azithromycin 20 mg/kg oral single dose (MDA); OR topical tetracycline BD × 6 wks"],
    ["F", "Facial cleanliness", "Reduce ocular discharge; disrupt fly-mediated transmission"],
    ["E", "Environmental improvement", "Clean water supply, sanitation, reduce fly breeding sites"],
  ],
  [8, 22, 70]
));
children.push(spacer());
children.push(importantBox("SAFE = Surgery, Antibiotics, Facial cleanliness, Environmental improvement. This is the WHO-endorsed strategy for trachoma elimination — a very high-yield exam topic."));
children.push(spacer());
children.push(bulletItem("Trachoma endemic in >55 countries; closely linked to poverty and poor sanitation"));
children.push(bulletItem("Repeated C. trachomatis infections → progressive tarsal conjunctival scarring → entropion → trichiasis → corneal abrasion → vascularisation → opacity"));
children.push(bulletItem("Once trachomatous keratopathy develops: PK required but outcomes POOR (vascularized cornea → high rejection rate, ongoing ocular surface disease)"));
children.push(bulletItem("Prevention by SAFE is far superior to surgical correction of established blindness"));
children.push(spacer());

children.push(subHeading("5.2 Xerophthalmia / Vitamin A Deficiency (VAD)"));
children.push(subSubHeading("WHO Classification of Xerophthalmia:"));
children.push(makeTable(
  ["Stage", "Code", "Clinical Feature"],
  [
    ["Night blindness", "XN", "Earliest sign; impaired dark adaptation"],
    ["Conjunctival xerosis", "X1A", "Dry, lustreless conjunctiva"],
    ["Bitot's spots", "X1B", "Foamy, cheesy spots — triangular, lateral conjunctiva"],
    ["Corneal xerosis", "X2", "Dry, hazy cornea — reversible with treatment"],
    ["Corneal ulceration < 1/3 surface", "X3A", "Sight-threatening; needs urgent Vit A"],
    ["Keratomalacia ≥ 1/3 surface", "X3B", "Corneal melt — irreversible blindness"],
    ["Corneal scar", "XS", "End-stage scarring"],
    ["Xerophthalmic fundus", "XF", "White spots peripheral retina — rare"],
  ],
  [35, 12, 53]
));
children.push(spacer());
children.push(importantBox("X3B (Keratomalacia) = full-thickness corneal melt → irreversible blindness. X3A and earlier stages are REVERSIBLE with Vitamin A."));
children.push(spacer());

children.push(subSubHeading("Prevention & Control Strategies:"));
children.push(bulletItem("Vitamin A supplementation: 100,000 IU (< 12 months); 200,000 IU (1–5 years) — every 6 months"));
children.push(bulletItem("Dose at diagnosis: Day 1 + Day 2 + Day 14 (WHO protocol)"));
children.push(bulletItem("Dietary diversification: dark green leafy vegetables, yellow/orange fruits, eggs, liver"));
children.push(bulletItem("Food fortification: cooking oil, sugar, flour with Vit A"));
children.push(bulletItem("Treat precipitating conditions: diarrhoea, measles, PEM — these trigger keratomalacia"));
children.push(bulletItem("Integration with ICDS (Integrated Child Development Services) and NPCB"));
children.push(spacer());

children.push(subHeading("5.3 Corneal Infections — Management Strategy"));
children.push(bulletItem("Train primary health workers to identify red eye + corneal ulcer → immediate referral"));
children.push(bulletItem("Ensure availability of topical natamycin (antifungal), moxifloxacin (antibacterial), acyclovir (antiviral) at PHC level"));
children.push(bulletItem("STRICT BAN on topical steroids in undifferentiated red eye at PHC level — exacerbates fungal/viral keratitis"));
children.push(bulletItem("Awareness campaigns against Traditional Eye Medicine (TEM)"));
children.push(bulletItem("Acyclovir 400 mg BD as prophylaxis for recurrent HSV keratitis (HEDS trial evidence)"));
children.push(bulletItem("Telemedicine + slit-lamp photography for remote consultation in corneal disease"));
children.push(spacer());
children.push(warningBox("Misuse of topical steroids is a major preventable cause of worsening corneal ulcers. This is a common exam scenario."));
children.push(spacer());

children.push(subHeading("5.4 Eye Banking & Corneal Transplantation"));
children.push(subSubHeading("Vision 2020 Targets for India:"));
children.push(makeTable(
  ["Infrastructure Target", "Number"],
  [
    ["Eye Bank Training Centres (EBTCs)", "20"],
    ["Eye Banks (EBs)", "200"],
    ["Eye Retrieval Centres (ERCs)", "2,000"],
    ["Corneal transplants/year required", "100,000"],
    ["Corneas to be collected annually (target)", "200,000"],
  ],
  [60, 40]
));
children.push(spacer());
children.push(subSubHeading("Current Status (India, 2020):"));
children.push(bulletItem("Functional EBs/ERCs: ~380 (against target of 2,200)"));
children.push(bulletItem("Corneal transplants performed: <30,000/year (against target of 100,000)"));
children.push(bulletItem("Tissues collected: ~47,000/year (against target of 200,000)"));
children.push(spacer());
children.push(warningBox("India performs <30,000 corneal transplants/year against a need of 100,000 — a 3-fold deficit. This is the single biggest challenge in addressing corneal blindness."));
children.push(spacer());

children.push(subSubHeading("Types of Keratoplasty:"));
children.push(makeTable(
  ["Procedure", "Indication", "Notes"],
  [
    ["Penetrating Keratoplasty (PK)", "Full-thickness disease, corneal scar", "Most performed; full-thickness graft"],
    ["DALK (Deep Anterior Lamellar)", "Stromal disease + healthy endothelium", "Preserves host endothelium; zero endothelial rejection"],
    ["DSAEK", "Fuchs' dystrophy, bullous keratopathy", "Automated Descemet stripping; faster visual recovery"],
    ["DMEK", "Fuchs' dystrophy", "Descemet membrane only; best visual outcomes; technically demanding"],
    ["Keratoprosthesis (KPro)", "Failed multiple grafts, vascularized cornea", "Boston KPro; used when donor graft not feasible"],
  ],
  [28, 32, 40]
));
children.push(spacer());
children.push(subSubHeading("Eye Bank Preservation Media:"));
children.push(makeTable(
  ["Medium", "Storage", "Duration", "Use"],
  [
    ["McCarey-Kaufman (MK)", "4°C", "4 days", "Short-term; inexpensive; widely used in developing countries"],
    ["Optisol-GS", "4°C", "14 days", "Standard in developed countries; superior endothelial preservation"],
    ["Cornisol", "4°C", "14 days", "Intermediate; more affordable alternative to Optisol"],
    ["Organ culture", "34°C", "28–35 days", "European standard; allows extended storage and distribution"],
  ],
  [25, 15, 15, 45]
));
children.push(spacer());
children.push(importantBox("Optisol is the standard preservation medium in developed countries (up to 14 days). MK medium used in India due to cost; limits distribution radius to ~4 days."));
children.push(spacer());

children.push(subSubHeading("Causes of Corneal Graft Failure:"));
children.push(bulletItem("Immunological rejection — most common avoidable cause"));
children.push(bulletItem("Primary donor failure — poor tissue quality at procurement"));
children.push(bulletItem("Recurrence of original disease (herpes, fungal, Acanthamoeba)"));
children.push(bulletItem("Glaucoma — secondary; IOP elevation damages graft endothelium"));
children.push(bulletItem("Endothelial cell loss — progressive; limits graft lifespan"));
children.push(spacer());

children.push(subHeading("5.5 Ocular Trauma Prevention"));
children.push(bulletItem("Protective eyewear in agricultural, construction, industrial settings (legislation and awareness)"));
children.push(bulletItem("Chemical safety and first-aid training in schools and workplaces"));
children.push(bulletItem("School-based injury prevention programs for children"));
children.push(bulletItem("Onchocerciasis control: Ivermectin MDA to prevent corneal involvement (river blindness)"));
children.push(spacer());

// ─── SECTION 6: ACHIEVEMENTS ─────────────────────────────────────────────────
children.push(sectionHeading("6. Achievements of Vision 2020"));
children.push(spacer(0.5));

children.push(subHeading("6.1 Global Achievements"));
children.push(greenBox("Over 100 WHO member states directly involved; national Vision 2020 committees and action plans established in most low-middle income countries."));
children.push(spacer(0.5));
children.push(greenBox("Age-adjusted prevalence of blindness has DECREASED over 3 decades — despite population growth. A major public health success."));
children.push(spacer(0.5));
children.push(greenBox("Trachoma eliminated as a public health problem in >20 countries including Morocco, Ghana, Cambodia, Laos, Myanmar, Vanuatu (GET2020 alliance)."));
children.push(spacer(0.5));
children.push(greenBox("Onchocerciasis eliminated from the Americas and several African foci through Ivermectin MDA; river blindness no longer a major burden in Latin America."));
children.push(spacer(0.5));
children.push(greenBox("India's Cataract Surgical Rate (CSR) rose from ~2,000/million/year in early 2000s to >7,000/million/year — among the highest outputs globally."));
children.push(spacer());

children.push(subHeading("6.2 Achievements in Corneal Blindness"));
children.push(makeTable(
  ["Area", "Achievement"],
  [
    ["Trachoma (India)", "India declared free of trachoma as a public health problem by WHO"],
    ["Eye Bank infrastructure", "380+ functional EBs/ERCs established (vs. near-zero in 1990s)"],
    ["Hospital Cornea Retrieval Program (HCRP)", "Dramatically increased donation rates from hospital deaths"],
    ["Corneal surgeon training", "Training avenues for corneal surgeons and eye bank technicians greatly expanded"],
    ["Vitamin A coverage", "Supplementation coverage >90% in many Indian states — reduced keratomalacia burden"],
    ["Public awareness", "Mass media campaigns increased voluntary eye donation awareness"],
    ["HSV keratitis prophylaxis", "Acyclovir prophylaxis widely available — reduces recurrence and corneal scarring"],
    ["WHO fellowship support", "Intra-country fellowships in corneal transplantation, vitreoretinal, laser, and paediatric ophthalmology"],
  ],
  [35, 65]
));
children.push(spacer());

// ─── SECTION 7: CHALLENGES ───────────────────────────────────────────────────
children.push(sectionHeading("7. Challenges in Addressing Corneal Blindness"));
children.push(spacer(0.5));

children.push(makeTable(
  ["Challenge", "Details", "Magnitude"],
  [
    ["Donor cornea shortage", "India needs 200,000 corneas/year; collects only 47,000 — 4-fold deficit", "CRITICAL"],
    ["Socio-cultural barriers", "Religious beliefs, myths about disfigurement, grief of family — low eye donation rates", "HIGH"],
    ["Geographic maldistribution", "EBs concentrated in cities; rural areas have little access to keratoplasty", "HIGH"],
    ["Late presentation", "Patients arrive at tertiary care with vascularized, opaque corneas — poor surgical outcome", "HIGH"],
    ["Topical steroid misuse", "GPs prescribing steroids for red eye → worsening fungal/viral keratitis → irreversible scarring", "HIGH"],
    ["Traditional eye medicine", "TEM (cow urine, plant extracts) used in rural areas — direct corneal toxicity and infection", "HIGH"],
    ["Human resource deficit", "Shortage of trained corneal surgeons and eye bank technicians, esp. in tier-2/3 cities", "MODERATE"],
    ["Preservation medium cost", "Optisol/Cornisol more expensive than MK medium — limits use in resource-limited settings", "MODERATE"],
    ["Post-transplant follow-up", "Patients unable to attend follow-up in cities → missed graft rejection episodes → graft failure", "MODERATE"],
    ["VAD residual burden", "Subclinical VAD and keratomalacia still occur in tribal, flood-prone, and conflict areas", "MODERATE"],
    ["Trachoma residual pockets", "Active trachoma persists in Rajasthan, UP, Gujarat; reinfection after MDA due to poor sanitation", "MODERATE"],
    ["COVID-19 disruption", "Eye donation and transplant programs severely disrupted 2020–21; waiting lists lengthened", "MODERATE"],
  ],
  [30, 55, 15]
));
children.push(spacer());

children.push(warningBox("The gap between corneal transplant need (~100,000/year) and actual performance (<30,000/year) in India is the single most important unresolved challenge in addressing corneal blindness under Vision 2020."));
children.push(spacer());

// ─── SECTION 8: FUTURE / POST-2020 ───────────────────────────────────────────
children.push(sectionHeading("8. Post-2020 — Future Directions"));
children.push(spacer(0.5));

children.push(bulletItem("IAPB 2030 IN SIGHT — successor initiative; eye health integrated into UN SDG/Universal Health Coverage framework"));
children.push(bulletItem("WHO Integrated People-Centred Eye Care (IPEC) — community-based comprehensive approach"));
children.push(bulletItem("Bioengineered corneas and cultured corneal endothelial cell therapy — to circumvent donor shortage"));
children.push(bulletItem("Keratoprostheses (Boston KPro, MICOF) for failed grafts and heavily vascularized corneas"));
children.push(bulletItem("AI-based trachoma grading (TF/TI) from smartphone photographs for field surveys"));
children.push(bulletItem("Telemedicine for remote corneal disease screening and follow-up"));
children.push(bulletItem("Regulatory frameworks for international corneal tissue sharing — streamline cross-border distribution"));
children.push(bulletItem("Digital Hospital Cornea Retrieval Programs — real-time death alerts to mobilise eye bank teams"));
children.push(spacer());

// ─── SECTION 9: RAPID RECALL TABLES ──────────────────────────────────────────
children.push(sectionHeading("9. Rapid-Recall Tables for Exam"));
children.push(spacer(0.5));

children.push(subHeading("9.1 One-Page Summary"));
children.push(makeTable(
  ["Parameter", "Key Fact"],
  [
    ["Launch date", "18 February 1999"],
    ["Launched by", "WHO + IAPB"],
    ["Based on", "Rights-based framework (sight = human right)"],
    ["Goal", "Eliminate avoidable blindness by 2020"],
    ["Guiding acronym", "ISEE (Integration, Sustainability, Equity, Evidence-based)"],
    ["Target diseases (India)", "Cataract, Refractive error, Childhood blindness, Corneal blindness, Glaucoma, Diabetic retinopathy"],
    ["India four-tier system", "20 CoE / 200 Training / 2000 Service / 20,000 Vision Centres"],
    ["Eye bank target (India)", "20 EBTCs / 200 EBs / 2000 ERCs"],
    ["Trachoma strategy", "SAFE (Surgery, Antibiotics, Facial cleanliness, Environment)"],
    ["Corneal blindness rank (India)", "2nd most common preventable blindness"],
    ["India corneal transplant gap", "Need 100,000/yr; performing <30,000/yr"],
    ["Standard preservation medium", "Optisol (14 days) — standard; MK medium (4 days) — India common"],
    ["Vit A supplementation dose", "100,000 IU (<1 yr); 200,000 IU (>1 yr) — every 6 months"],
    ["Irreversible xerophthalmia stage", "X3B — Keratomalacia (≥1/3 corneal melt)"],
    ["Post-2020 initiative", "IAPB 2030 IN SIGHT; WHO IPEC"],
    ["Global action plan target", "25% reduction in avoidable VI from 2010 baseline by 2019"],
  ],
  [40, 60]
));
children.push(spacer());

children.push(subHeading("9.2 SAFE Strategy — Exam Mnemonics"));
children.push(makeTable(
  ["S", "A", "F", "E"],
  [["Surgery for trichiasis/entropion\n(Bilamellar tarsal rotation)", "Antibiotics\n(Azithromycin 20 mg/kg OD)\nor topical tetracycline", "Facial cleanliness\n(reduce ocular discharge)", "Environmental improvement\n(clean water, sanitation)"]],
  [25, 25, 25, 25]
));
children.push(spacer());

children.push(subHeading("9.3 Xerophthalmia Classification (WHO)"));
children.push(makeTable(
  ["Code", "Stage", "Reversible?"],
  [
    ["XN", "Night blindness", "YES"],
    ["X1A", "Conjunctival xerosis", "YES"],
    ["X1B", "Bitot's spots", "YES"],
    ["X2", "Corneal xerosis", "YES (with urgent Vit A)"],
    ["X3A", "Corneal ulceration < 1/3", "PARTIAL"],
    ["X3B", "Keratomalacia ≥ 1/3", "NO — irreversible blindness"],
    ["XS", "Corneal scar", "NO"],
    ["XF", "Xerophthalmic fundus", "Partial"],
  ],
  [12, 60, 28]
));
children.push(spacer());

children.push(subHeading("9.4 Keratoplasty Types — Quick Recall"));
children.push(makeTable(
  ["Type", "Layers Replaced", "Best Indication"],
  [
    ["PK (Penetrating keratoplasty)", "Full thickness", "Corneal scar, trachoma, trauma"],
    ["DALK", "Stroma + epithelium (Descemet's intact)", "Keratoconus, stromal dystrophies"],
    ["DSAEK", "Descemet's + endothelium (automated)", "Fuchs' dystrophy, bullous keratopathy"],
    ["DMEK", "Descemet's membrane only", "Fuchs' — best visual acuity"],
    ["KPro (Boston KPro)", "Synthetic corneal button", "Failed multiple grafts, vascularized cornea"],
  ],
  [30, 30, 40]
));
children.push(spacer());

// ─── SECTION 10: PREVIOUS EXAM Q&A ──────────────────────────────────────────
children.push(sectionHeading("10. High-Yield Exam Questions & Model Answers"));
children.push(spacer(0.5));

const qas = [
  {
    q: "Q1. What is Vision 2020? What are its objectives?",
    a: "Vision 2020: The Right to Sight was launched on 18th February 1999 by WHO and IAPB. It is a global initiative to eliminate avoidable blindness by the year 2020, based on the concept of sight as a fundamental human right. Objectives: (1) Develop sustainable national eye care systems; (2) Eliminate avoidable blindness from cataract, refractive errors, childhood blindness, trachoma, corneal blindness, glaucoma, and diabetic retinopathy; (3) Strengthen human resources and infrastructure at all levels; (4) Promote equitable access to eye care services."
  },
  {
    q: "Q2. Write the SAFE strategy for trachoma.",
    a: "S = Surgery (bilamellar tarsal rotation for trichiasis/entropion); A = Antibiotics (azithromycin 20 mg/kg single oral dose as MDA, or topical tetracycline); F = Facial cleanliness (reduce ocular secretions, disrupt fly-transmission); E = Environmental improvement (clean water, sanitation, reduce fly breeding). This is the WHO-endorsed strategy to eliminate trachoma as a blinding disease. Azithromycin MDA is given annually in endemic communities."
  },
  {
    q: "Q3. What are the challenges in addressing corneal blindness under Vision 2020?",
    a: "Key challenges: (1) Severe donor cornea shortage — India needs 100,000 transplants/year but performs <30,000; only 47,000 tissues collected (4-fold deficit); (2) Socio-cultural barriers to eye donation — religious beliefs, myths; (3) Geographic maldistribution of eye banks — concentrated in cities; (4) Late presentation with vascularized opaque corneas — poor surgical outcomes; (5) Topical steroid misuse at primary level worsening keratitis; (6) Traditional eye medicine (TEM) causing iatrogenic corneal damage; (7) Shortage of trained corneal surgeons; (8) Post-transplant follow-up inaccessibility; (9) Residual VAD and trachoma in remote areas; (10) COVID-19 disruption of donation/transplant programs."
  },
  {
    q: "Q4. What is the four-tier structure proposed for India under Vision 2020?",
    a: "Tier 1 — 20 Centres of Excellence: complex surgery (corneal transplant, vitreoretinal, paediatric ophthalmology), research and super-speciality training. Tier 2 — 200 Training Centres: ophthalmologist training, advanced procedures, district-level oversight. Tier 3 — 2,000 Service/District Centres: cataract surgery, glaucoma management, DR screening, outreach coordination. Tier 4 — 20,000 Vision Centres: primary eye care, refraction, Vitamin A supplementation, screening, referral."
  },
  {
    q: "Q5. What is the role of eye banking in Vision 2020?",
    a: "Eye banking is the rehabilitative cornerstone of Vision 2020's corneal blindness strategy. Functions: procurement from voluntary donors and HCRP (Hospital Cornea Retrieval Programs); serology screening (HIV, HBsAg, HCV); tissue preservation (MK medium 4 days; Optisol 14 days); endothelial cell density assessment; equitable distribution to transplanting surgeons. Vision 2020 India targets: 20 EBTCs, 200 EBs, 2,000 ERCs. Current status: ~380 functional, performing <30,000 transplants/year against a target of 100,000."
  },
  {
    q: "Q6. What are the Xerophthalmia stages and which is irreversible?",
    a: "WHO Classification: XN (night blindness), X1A (conjunctival xerosis), X1B (Bitot's spots), X2 (corneal xerosis), X3A (corneal ulcer < 1/3), X3B (keratomalacia ≥ 1/3 — IRREVERSIBLE), XS (corneal scar), XF (xerophthalmic fundus). X3B Keratomalacia is the irreversible stage — full-thickness corneal melt leading to permanent blindness. Stages up to X3A are reversible with prompt Vitamin A treatment. Vitamin A dosing under National Program: 100,000 IU for < 1 year; 200,000 IU for 1–5 years, given every 6 months."
  },
];

for (const qa of qas) {
  children.push(new Paragraph({
    spacing: { before: pt(6), after: pt(2) },
    shading: { type: ShadingType.SOLID, color: LIGHT_BLUE, fill: LIGHT_BLUE },
    children: [new TextRun({ text: qa.q, bold: true, color: DARK_BLUE, size: pt(11), font: "Calibri" })]
  }));
  children.push(new Paragraph({
    spacing: { before: pt(2), after: pt(6) },
    indent: { left: 200 },
    children: [new TextRun({ text: qa.a, size: pt(10.5), font: "Calibri", color: DARK_GRAY })]
  }));
}

children.push(spacer());

// ─── FOOTER NOTE ─────────────────────────────────────────────────────────────
children.push(new Table({
  width: { size: 100, type: WidthType.PERCENTAGE },
  rows: [new TableRow({ children: [new TableCell({
    shading: { type: ShadingType.SOLID, color: DARK_BLUE, fill: DARK_BLUE },
    margins: { top: 150, bottom: 150, left: 300, right: 300 },
    children: [
      new Paragraph({
        alignment: AlignmentType.CENTER,
        children: [new TextRun({ text: "Sources: Park's Textbook of Preventive & Social Medicine | Kanski's Clinical Ophthalmology (10th ed.) | WHO Vision 2020 Action Plans | NAMS Annals | PMC3831688", color: LIGHT_BLUE, size: pt(9), font: "Calibri", italics: true })]
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        children: [new TextRun({ text: "Compiled for PG Ophthalmology & PSM Exam Revision  •  Vision 2020: The Right to Sight", color: ACCENT_GOLD, size: pt(9.5), font: "Calibri", bold: true })]
      }),
    ]
  })]})],
}));

// ─── ASSEMBLE DOCUMENT ───────────────────────────────────────────────────────
const doc = new Document({
  creator: "Orris Medical AI",
  title: "Vision 2020 — The Right to Sight: Comprehensive Exam Summary",
  description: "PG Ophthalmology and PSM exam-ready revision document",
  styles: {
    default: {
      document: { run: { font: "Calibri", size: pt(11), color: DARK_GRAY } }
    }
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 720, bottom: 720, left: 900, right: 900 }
      }
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          alignment: AlignmentType.RIGHT,
          border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: ACCENT_GOLD } },
          children: [
            new TextRun({ text: "VISION 2020: The Right to Sight  |  Exam Summary  |  ", color: MED_BLUE, size: pt(9), font: "Calibri" }),
            new TextRun({ text: "PG Ophthalmology", bold: true, color: DARK_BLUE, size: pt(9), font: "Calibri" })
          ]
        })]
      })
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          border: { top: { style: BorderStyle.SINGLE, size: 4, color: ACCENT_GOLD } },
          children: [
            new TextRun({ text: "Page ", color: DARK_GRAY, size: pt(9), font: "Calibri" }),
            new PageNumber({ type: "current", color: MED_BLUE, size: pt(9) }),
            new TextRun({ text: "  •  Vision 2020 Exam Summary  •  Orris Medical AI", color: DARK_GRAY, size: pt(9), font: "Calibri" }),
          ]
        })]
      })
    },
    children
  }]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync("/home/daytona/workspace/vision2020-docx/Vision2020_ExamSummary.docx", buffer);
  console.log("Document created successfully.");
}).catch(err => {
  console.error("Error:", err);
  process.exit(1);
});

cd /home/daytona/workspace/vision2020-docx && node generate.js 2>&1

~/vision2020-docx/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/vision2020-docx/generate.js'

~/vision2020-docx/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/vision2020-docx/generate.js'

cd /home/daytona/workspace/vision2020-docx && node generate.js 2>&1

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

ls -lh /home/daytona/workspace/vision2020-docx/ && python3 -c "import zipfile; z…